Dr. Neil Iyengar & Dr. Erika Hamilton - First-Line TNBC: How TRO-Breast02 & ASCENT-03 Change the Game

Community Health Media · Dec 11, 2025 · 23m

Triple-negative breast cancer has entered a new era.

At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.

Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.

#BreastCancer #TNBC #TripleNegativeBreastCancer #TROP2 #ADCs #TDXd #SacituzumabGovitecan #ASCENT03 #TROB02 #ESMO2025 #Oncology #CancerResearch #CHM

–

Thanks for watching!

Our…